[1]袁志斌.ZevalinTM:一种放射免疫治疗新药[J].国际放射医学核医学杂志,2002,26(5):225-227.
　YUAN Zhi-bin.ZevalinTM: A new radioimmunotherapy agent[J].International Journal of Radiation Medicine and Nuclear Medicine,2002,26(5):225-227.
点击复制

ZevalinTM:一种放射免疫治疗新药(/HTML)
分享到：

《国际放射医学核医学杂志》[ISSN:1673-4114/CN:12-1381/R]

卷:
26
期数:
2002年第5期
页码:
225-227
栏目:
综述
出版日期:
1900-01-01

文章信息/Info

Title:
ZevalinTM: A new radioimmunotherapy agent
作者:
袁志斌
200233 上海, 上海市第六人民医院核医学科
Author(s):
YUAN Zhi-bin
Department of Nuclear Medicine, Shanghai 6th People’s Hospital, Shanghai 2000233, China
关键词:
放射免疫治疗; 非霍奇金氏淋巴瘤; 90-钇; CD20抗原; Zevalin
Keywords:
radioimmunotherapy; non-Hodgkin’s lymphoma; Yittrium-90; CD20 antigen; Zevalin
分类号:
R817.5
摘要:
放射免疫治疗是放射性核素治疗的重要组成和研究的重点之一。ZevalinTM第一个得到FDA批准的用于治疗复发或顽固性低度恶性非霍奇金氏淋巴瘤的放射免疫治疗制剂。本文综述了该制剂的组成、治疗方案、药理作用机制、辐射剂量和临床试验结果等方面的内容。
Abstract:
Radioimmunotherapy is a major component of radionuclide therapy and always being the main field of re-search.ZevalinTM is the first FDA marketing approved radioimmunotherapy agent which is indicated for the treatment of relapsed or refractory low grade non-Hodgkin’s lymphoma.In this review,the component,therapeutic regimen,pharmacological mechanism,radiation dosage and clinical experiment result of ZevalinTM are described respectively.

参考文献/References:

[1] Srivastava S, Dadachova E. Recent advances in radionuclide therapy[J]. Semin Nucl Med, 2001, 31(4):330-341.
[2] Krasner C, Joyce RM. Zevalin:90-Yttrium labeled anti-CD20(Ibritumomabtiuxetan), a new treatment for non-Hodgkin’s lymphoma[J]. Curr Pharm Biotechol, 2001, 2(4):341-349.
[3] Wagner HN Jr, Wiseman GA, Marcus CS, et al. Administration guidelines for radioimmunotherapy of non-Hodgkin’s lymphoma with 90Y labelled anti-CD20 monoclonal antibody[J]. J Nucl Med, 2002, 43(2):267-272.
[4] Hainsworth JD. Monoclonal antibody therapy in lymphoid malignancies[J]. Oncologist, 2000, 5(5):376-384.
[5] Wiseman GA, White CA, Sparks RB, et al. Biodistribution and dosimetry results froma phase Ⅲ prospectively randomized controlled trial ZevalinTM radioimmunotherapy for low-grade, follicular, or transformed B-cell non-Hodgkin’s lymphoma[J]. Critical Revi Oncol Hematol,2001, 39(2):181-194.
[6] Janakiraman N, Gutheil J, Schilder RJ, et al. Phase Ⅰ/Ⅱ trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refratory CD20(+) B-cell non-Hodgkin’s lymphoma[J]. J Clin Oncol, 1999, 17(12):3793-3803.

相似文献/References:

[1]杨卫东,汪静.肿瘤核素靶向治疗新进展[J].国际放射医学核医学杂志,2015,39(1):19.[doi:10.3760/cma.j.issn.1673-4114.2015.01.006]
　Yang Weidong,Wang Jing.Advance progress of radionuclide target tumor therapy[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(5):19.[doi:10.3760/cma.j.issn.1673-4114.2015.01.006]
[2]田源,张良安.放射免疫治疗中的α核素微剂量研究[J].国际放射医学核医学杂志,2006,30(1):39.
　TIAN Yuan,ZHANG Liang-an.A review of microdosimetric study in alpha particle radioimmunotherapy[J].International Journal of Radiation Medicine and Nuclear Medicine,2006,30(5):39.
[3]陈立波,朱瑞森.Bexxar治疗非霍奇金淋巴瘤的研究现状[J].国际放射医学核医学杂志,2005,29(2):67.
　CHEN Li-bo,ZHU Rui-sen.Current status of Bexxar for treatment of non-Hodgkin’s lymphoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2005,29(5):67.
[4]高云朝.恶性胶质瘤的放射免疫治疗[J].国际放射医学核医学杂志,2004,28(4):149.
　GAO Yun-chao.Radioimmunotherapy for malignant glioma[J].International Journal of Radiation Medicine and Nuclear Medicine,2004,28(5):149.
[5]张弘.用于放免治疗的核素研究进展[J].国际放射医学核医学杂志,2003,27(4):148.
　ZHANG Hong.Advances in radionuclide for radioimmunotherapy[J].International Journal of Radiation Medicine and Nuclear Medicine,2003,27(5):148.
[6]李敏杰.胰腺癌的放射免疫治疗进展[J].国际放射医学核医学杂志,2003,27(4):154.
　LI Min-jie.Radioimmunotherapy of pancreatic cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2003,27(5):154.
[7]任均田,林学颜.放射免疫显像与治疗的应用进展[J].国际放射医学核医学杂志,1995,19(2):57.
[8]唐刚华,王世真.生物素-亲合素系统在核医学中的应用[J].国际放射医学核医学杂志,1997,21(4):145.
[9]田嘉禾.关于放射免疫治疗的新思考[J].国际放射医学核医学杂志,1997,21(5):249.
[10]杨连君,司晓辉,隋延仿,等.90Y标记单克隆抗体导向治疗肿瘤[J].国际放射医学核医学杂志,1996,20(5):205.

备注/Memo

备注/Memo:
收稿日期:2002-05-23。
作者简介:袁志斌(1969-),男,副主任技师,主要从事放射性药物的研究工作。
更新日期/Last Update: 1900-01-01